Kondo S, Asano M, Suzuki H
Bioscience Research Department, Toagosei Chemical Industry Tsukuba Research Laboratory, Ibaraki, Japan.
Biochem Biophys Res Commun. 1993 Aug 16;194(3):1234-41. doi: 10.1006/bbrc.1993.1955.
Angiogenesis is essential for successful tumor growth in vivo. There is a hypothesis that tumors secrete a putative tumor angiogenic factor (TAF) to facilitate blood vessel formations. Although several endothelial growth factors have been reported, it remains unclear whether these factors function as TAF in vivo. Vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF) is a vascular endothelial mitogen that can increase blood vessel permeability. We have established a cell line (HeLa/v5), which secretes VEGF/VPF, by transfection of human VEGF/VPF cDNA. HeLa/v5 showed higher angiogenic activity, taken/planted ratio and tumor growth rate than the control transformant (HeLa/c), when they were implanted to nude mice. Administration of a polyclonal antibody, which neutralizes the mitogenic activity of VEGF/VPF in vitro, to the tumor implanted nude mice suppressed the in vivo growth of HeLa/v5. Furthermore, all 8 tumor cell lines we tested secrete VEGF/VPF into culture media. Our findings indicate that VEGF/VPF is a tumor angiogenic factor.
血管生成对于体内肿瘤的成功生长至关重要。有一种假说认为,肿瘤分泌一种假定的肿瘤血管生成因子(TAF)以促进血管形成。尽管已经报道了几种内皮生长因子,但这些因子在体内是否作为TAF发挥作用仍不清楚。血管内皮生长因子(VEGF)/血管通透因子(VPF)是一种血管内皮有丝分裂原,可增加血管通透性。我们通过转染人VEGF/VPF cDNA建立了一种分泌VEGF/VPF的细胞系(HeLa/v5)。当将HeLa/v5接种到裸鼠体内时,其显示出比对照转化体(HeLa/c)更高的血管生成活性、接种/种植率和肿瘤生长速率。向接种肿瘤的裸鼠施用一种在体外中和VEGF/VPF有丝分裂活性的多克隆抗体,可抑制HeLa/v5在体内的生长。此外,我们测试的所有8种肿瘤细胞系均将VEGF/VPF分泌到培养基中。我们的研究结果表明,VEGF/VPF是一种肿瘤血管生成因子。